

PORTOLA PHARMACEUTICALS INC

Form 4

December 10, 2015

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Fullerton Management Pte Ltd

(Last) (First) (Middle)

60B ORCHARD ROAD #06-18,
TOWER 2, THE
ATRIUM@ORCHARD

(Street)

SINGAPORE, U0 238891

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol

PORTOLA PHARMACEUTICALS
INC [PTLA]

3. Date of Earliest Transaction
(Month/Day/Year)
12/09/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____ Form filed by One Reporting Person
__X__ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------------|---|---|--------------------------------------|---|--|--|---|
| | | | Code | V | Amount | (A) or (D) | Price |
| Common stock | 12/09/2015 | | P | | 750,000 | A | \$ 48 |
| | | | | | 6,583,568 | I | |

See
footnote
(1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

Edgar Filing: PORTOLA PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr |
|---|--|---|---|--------------------------------------|--|--|---|---|--|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |

Reporting Owners

| Reporting Owner Name / Address | Relationships |
|--|----------------------------------|
| | Director 10% Owner Officer Other |
| Fullerton Management Pte Ltd 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891 | X |
| Temasek Holdings (Private) Ltd 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891 | X |

Signatures

/s/ Christina Choo, Authorised Signatory, Temasek Holdings (Private)
Limited 12/10/2015

__Signature of Reporting Person Date

/s/ Cheong Kok Tim, Director, Fullerton Management Pte Ltd 12/10/2015

__Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Fullerton Management Pte Ltd ("FMPL") indirectly owns 6,583,568 shares of the Issuer's common stock ("Shares") through two indirect wholly-owned subsidiaries, V-Sciences Investments Pte Ltd ("V-Sciences") which owns 750,000 Shares and Maxwell (Mauritius) Pte Ltd ("Maxwell") which owns 5,833,568 Shares. V-Sciences is wholly-owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. Maxwell is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd which is wholly owned by FMPL. FMPL is wholly-owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of common stock owned by V-Sciences and Maxwell, collectively.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: PORTOLA PHARMACEUTICALS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.